Short Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Decreases By 23.0%

Delcath Systems, Inc. (NASDAQ:DCTH) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,040,000 shares, a decrease of 23.0% from the December 15th total of 1,350,000 shares. Based on an average trading volume of 386,900 shares, the short-interest ratio is currently 2.7 days.

Delcath Systems Stock Up 0.2 %

Shares of Delcath Systems stock opened at $12.71 on Thursday. Delcath Systems has a 52 week low of $3.70 and a 52 week high of $13.30. The business has a 50 day moving average price of $11.33 and a 200-day moving average price of $9.83. The company has a market cap of $406.39 million, a PE ratio of -9.41 and a beta of 0.87.

Hedge Funds Weigh In On Delcath Systems

Large investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Delcath Systems during the third quarter valued at approximately $102,000. Barclays PLC purchased a new position in shares of Delcath Systems in the 3rd quarter worth about $104,000. Jane Street Group LLC bought a new position in Delcath Systems during the third quarter valued at about $110,000. Riverwater Partners LLC purchased a new stake in Delcath Systems during the third quarter worth about $161,000. Finally, Virtu Financial LLC bought a new stake in Delcath Systems in the third quarter worth about $289,000. 61.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DCTH. StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Stephens restated a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a report on Tuesday. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.